Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Photodynamic Therapy and Probiotics in Halitosis Reduction
NCT03996044Phase 1Completed
- Sponsor
- University of Nove de Julho
- Start
- Jan 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised trial of urucum and Lactobacillus salivarius WB21 in halitosis (4 arms), sponsored by University of Nove de Julho. Primary endpoint: Change in halimetry (gas chromatography) at 30 days. Started Jan 2021; status: completed.
02
Drugs
urucumLactobacillus salivarius WB21
03
Conditions
halitosis
Beyond the preview
Go deeper on NCT03996044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03996044.